Dr. Ma on Utilizing Zanabrutinib in CLL

Shuo Ma, MD, PhD, associate professor of Medicine, Hematology and Oncology, Feinberg School of Medicine, Northwestern University, discusses the utilization of zanubrutinib (Brufkinsa) in chronic lymphocytic leukemia (CLL).

Zanubrutinib has found a role in everyday practice, such as in patients who have continued to benefit from inhibition of the BTK pathway but have developed an intolerance to ibrutinib (Imbruvica), Ma explains. Moreover, zanubrutinib is beneficial in patients who are not candidates for acalabrutinib (Calquence), including those patients who need to remain on a proton pump inhibitor and need long-term antacid medication, Ma adds.

The administration of zanubrutinib in these situations has proved to be favorable in practice, Ma concludes.